Showing results (21-30 of 67) with videos related to

Sort By:
Pageof 7
Oncology|April 7, 2026
Hypoxia-Induced microRNAs confer survival advantage in bladder cancer by fine-tuning oncogenic PathwaysTakaya Ohno, Yuki Nakajima, Yuki Yoshikawa, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|May 10, 2026
Comparative Efficacy of First-Line Immune Checkpoint Inhibitor-Based Combination Therapies in Patients With Sarcomatoid Renal Cell Carcinoma: A Japanese Multicenter Cohort StudyKeita Tamura, Yuto Matsushita, Hiromitsu Watanabe, et al.
In Vivo (Athens, Greece)|April 28, 2025
Cancer-induced Pain Is Associated With Poor Overall Survival of Urothelial Carcinoma Patients Treated With Enfortumab VedotinMamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 14, 2025
Comparison of Oncological Outcomes of Conventional Androgen Deprivation Therapy (ADT) and ADT Plus Androgen Receptor Signaling Inhibitor in Older Patients With Metastatic Castration-Sensitive Prostate CancerYutaka Yamamoto, Saizo Fujimoto, Mamoru Hashimoto, et al.
Translational Andrology and Urology|September 15, 2025
Upper urinary tract urothelial carcinoma patients show better overall response rate than bladder cancer patients during enfortumab vedotin treatment following pembrolizumabMamoru Hashimoto, Ken Fukiage, Kosei Taniguchi, et al.
Scientific Reports|January 13, 2026
Comparative efficacy of immune checkpoint inhibitor combination therapies by metastatic site in metastatic renal cell carcinomaShingo Toyoda, Lan Inoki, Mamoru Hashimoto, et al.
International Journal of Urology : Official Journal of the Japanese Urological Association|August 20, 2025
Role of Cytoreductive Nephrectomy in the Immune Checkpoint Inhibitor Era: A Multicenter Collaborative StudyTakuhisa Nukaya, Kiyoshi Takahara, Shingo Toyoda, et al.
Urologic Oncology|December 28, 2025
Comparison of prostate-specific antigen kinetics between androgen receptor signaling inhibitor doublet therapy and androgen receptor signaling inhibitor with docetaxel triplet therapy in patients with metastatic castration-sensitive prostate cancerTsuyoshi Morita, Yutaka Yamamoto, Saizo Fujimoto, et al.
Nature Communications|August 29, 2020
Senolytics prevent mt-DNA-induced inflammation and promote the survival of aged organs following transplantationJasper Iske, Midas Seyda, Timm Heinbokel, et al.
Oncotarget|January 5, 2018
The combination of preoperative platelet count and neutrophil lymphocyte ratio as a prognostic indicator in localized renal cell carcinomaTakuya Tsujino, Kazumasa Komura, Atsushi Ichihashi, et al.
Pageof 7